Legal status · Australia
Is Taspoglutide legal in Australia?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Taspoglutide is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 7 human studies are cited on its profile.
Taspoglutide in Australia at a glance
| Classification | Investigational, not registered |
|---|---|
| Note | Development halted in 2010. |
| TGA approval status | Not approved by TGA; investigational |
| Human studies cited | 7 of 7 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Taspoglutide profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
Taspoglutide is being studied in registered clinical trials but has not received TGA marketing approval in Australia.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Taspoglutide is
A once-weekly GLP-1 analogue that beat exenatide and sitagliptin on HbA1c in phase 3 and was halted in 2010 anyway. Its sponsor recorded the reason on the trial registry: high discontinuation rates mainly due to gastrointestinal tolerability and a risk mitigation plan for hypersensitivity reactions. Anti-drug antibodies were found in 46 to 49 percent of participants.
Taspoglutide is a synthetic analogue of human GLP-1 developed by Ipsen (BIM-51077) and licensed to Roche (R1583) for once-weekly subcutaneous injection in type 2 diabetes. It went into a phase 3 programme, T-emerge, of eight trials that randomised more than 6,000 people, and it is the most fully documented failure in the GLP-1 class: a drug that met its efficacy endpoints and was stopped for how people tolerated it.
Mechanism: 6 kg over 24 weeks. Its distinguishing property was pharmaceutical rather than pharmacological: it was formulated as a sustained-release weekly injection, one of the first in the class.
Regulatory history: Never approved. Phase 3 programme halted in 2010; ClinicalTrials.gov NCT01051011 records termination for high discontinuation rates mainly due to GI tolerability and a risk mitigation plan for hypersensitivity reactions. No marketing application located.
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Taspoglutide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Taspoglutide in other countries
Frequently asked questions
Is Taspoglutide legal in Australia?
No. Taspoglutide is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 7 human studies are cited on its profile. Note: Development halted in 2010.
Can I buy Taspoglutide in Australia?
No approved product exists to buy. In Australia Taspoglutide is classified as "Investigational, not registered", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Development halted in 2010.
Is Taspoglutide TGA approved?
No. In Australia Taspoglutide is classified as "Investigational, not registered", which is not a TGA marketing approval. For comparison, the US FDA status is: Never approved. Phase 3 programme halted in 2010; ClinicalTrials.gov NCT01051011 records termination for high discontinuation rates mainly due to GI tolerability and a risk mitigation plan for hypersensitivity reactions. No marketing application located.. On the evidence, 7 human studies are cited on its profile.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Taspoglutide live on its compound profile.
Taspoglutide profileThis page is general information about the regulatory status of Taspoglutide in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.